A

PriceAdagene

ADAG

Adagene Inc platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. It is principally engaged in research, development and production of monoclonal antibody drugs for cancers.  The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity as highlighted by the company's immunotherapy pipeline.

Historical stock price chart and annual return over the past years

-93%

4 years

% Total

ADAG
-49%

4 years

Annual Return

ADAG